- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lung RFA's midterm results beat expectations
More than 90% of patients undergoing radiofrequency ablation for primary and secondary lung cancer could outlive their treatment for two years or longer, provided they don't succumb to other causes. Researchers from Italy reported these findings at the Society of Interventional Radiology meeting in April.
More than 90% of patients undergoing radiofrequency ablation for primary and secondary lung cancer could outlive their treatment for two years or longer, provided they don't succumb to other causes. Researchers from Italy reported these findings at the Society of Interventional Radiology meeting in April.
Dr. Riccardo Lencioni and colleagues at the University of Pisa treated 186 nonoperable tumors in 106 patients enrolled in the multicenter Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE) trial. The study included 33 patients with non-small cell lung cancer, 53 with colorectal cancer metastases, and 20 with metastases from other types of malignancy.
RFA yielded high local tumor control rates and cancer-specific survival outcomes for patients with NSCLC or CRC metastases. CT follow-up three months after the procedure confirmed ablation's effectiveness rate at 93%. Cancer-specific survival rates for NSCLC and CRC metastases were 91% and 88% at one year and 91% and 72% at two years, respectively.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
